Commercializing cell and gene therapy: 4 ways to protect time-to-patient
Commercializing cell and gene therapy operations now means protecting time-to-patient across constrained, exception-heavy patient journeys. The planning challenge sits in exception handling, scale-out capacity, treatment-center visibility and dynamic resource...
Read more

